Ernexa Therapeutics Inc. conducted its 2025 Annual Meeting of Stockholders on June 2, 2025. The meeting included several key proposals. The election of director nominees James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, and William Wexler to the Board was approved. The appointment of Grant Thornton LLP as the independent registered public accounting firm for the 2025 fiscal year was ratified. Additionally, stockholders approved a non-binding advisory resolution regarding executive compensation and agreed on a three-year frequency for future advisory votes on executive compensation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.